Автор: Paul C. Guest Название: Multiplex Biomarker Techniques ISBN: 1493967290 ISBN-13(EAN): 9781493967292 Издательство: Springer Рейтинг: Цена: 20962.00 р. Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: This detailed book arrives as there is an increasing need for multiplex biomarker readouts for improved clinical management and to support the development of new drugs by pharmaceutical companies, due to continuous technical developments and new insights into the high complexity of many diseases.
Автор: Guest Paul C. Название: Multiplex Biomarker Techniques: Methods and Applications ISBN: 1493982850 ISBN-13(EAN): 9781493982851 Издательство: Springer Рейтинг: Цена: 15372.00 р. Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: This detailed book arrives as there is an increasing need for multiplex biomarker readouts for improved clinical management and to support the development of new drugs by pharmaceutical companies, due to continuous technical developments and new insights into the high complexity of many diseases.
Автор: Guest Название: Multiplex Biomarker Techniques ISBN: 1071623974 ISBN-13(EAN): 9781071623978 Издательство: Springer Рейтинг: Цена: 16769.00 р. Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: This detailed volume explores the application of multiplex biomarker methods in the critical area of COVID-19 research through state-of-the-art technologies in the fields of genomics, proteomics, transcriptomics, metabolomics, and imaging. The book features a series of protocols from labs across the globe employing multiplex molecular approaches, which can be applied to accelerate progress in the research of SARS-CoV-2 and other infectious illnesses. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and essential, Multiplex Biomarker Techniques: Methods and Applications for COVID-19 Disease Diagnosis and Risk Stratification serves as a vital resource for researchers in the areas of virology, metabolic diseases, respiratory disorders, as well as to clinical scientists, physicians, pharmacologists, and the healthcare services.
Автор: Youhe Gao Название: Urine Proteomics in Kidney Disease Biomarker Discovery ISBN: 9401795223 ISBN-13(EAN): 9789401795227 Издательство: Springer Рейтинг: Цена: 20962.00 р. Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: This book systematically summarizes the ideas and technologies used in urine proteome analysis. It argues that change is the core of biomarker definition since the body uses its homeostatic mechanisms to correct changes in the blood. This means that urine is probably a better source of biomarkers than blood. A roadmap to the urinary biomarker era is proposed, and researchers are reminded of the potential opportunities and risks in their study design. Kidney diseases are emphasized as they produce the most significant changes in urine. This book tries to show researchers and graduate students, who are in or entering the field, "all things considered" rather than "the current affair".
Автор: Feng Wang Название: Biomarker Methods in Drug Discovery and Development ISBN: 1617379255 ISBN-13(EAN): 9781617379253 Издательство: Springer Рейтинг: Цена: 25853.00 р. Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: In this book, expert researchers provide a tool box for those who have a general interest in biomarker research and for those currently specializing in certain technologies but desiring an understanding of other available methodologies.
Автор: Youhe Gao Название: Urine Proteomics in Kidney Disease Biomarker Discovery ISBN: 9402407243 ISBN-13(EAN): 9789402407242 Издательство: Springer Рейтинг: Цена: 18284.00 р. Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: This book systematically summarizes the ideas and technologies used in urine proteome analysis. It argues that change is the core of biomarker definition since the body uses its homeostatic mechanisms to correct changes in the blood. Kidney diseases are emphasized as they produce the most significant changes in urine.
Автор: Youhe Gao Название: Urine ISBN: 9811391084 ISBN-13(EAN): 9789811391088 Издательство: Springer Рейтинг: Цена: 19564.00 р. Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: This book demonstrates the potential of urine as a biomarker resource for early disease detection, covering the related theory, strategies, tools and findings. Biomarkers are measurable changes associated with diseases. Blood, as a critical part of its internal environment, is closely monitored and controlled by the body to maintain homeostasis, especially in the early stages of diseases. In contrast, urine, as a form of waste excreted by the body, collects a variety of substance changes. Accordingly, urine can offer an ideal resource for early biomarker discovery. In addition, urine is more stable than blood in vitro, and is easy to store and analyze. The book discusses exciting preliminary applications of urine biomarkers for diseases affecting major biological systems. Its main goal is to make scientists, clinicians and medical companies aware of this important, exciting, undeveloped, and profitable field.
Описание: This book demonstrates the potential of urine as a biomarker resource for early disease detection, covering the related theory, strategies, tools and findings. The book discusses exciting preliminary applications of urine biomarkers for diseases affecting major biological systems.
Описание: This book is oriented towards post-graduates and researchers with interest in proteomics and its applications in clinical biomarker discovery pipeline. Biomarker discovery has long been the research focus of many life scientists globally. However, the pipeline starting from discovery to validation to regulation as a diagnostic or therapeutic molecule follows a complex trajectory. This book aims to provide an in-depth synopsis on each of these developmental phases attendant to biomarker “life cycle” with emphasis on the emerging and significant role of proteomics. The book begins with a perspective on the role of biorepositories and need for biobanking practices in the developing world. The next chapter focuses on disease heterogeneity in context to geographical bias towards susceptibility to the disease and the role of multi-omics techniques to devise disruptive innovations towards biomarker discovery. Chapter 3 focuses on various omics-based platforms that are currently being used for biomarker discovery, their principles and workflow. Mass spectrometry is emerging as a powerful technology for discovery based studies and targeted validation. Chapter 4 aims at providing a glimpse of the basic workflow and considerations in mass spectrometry based studies. Rapid and aptly targeted research funding has often been deemed as one of the decisive factors enabling excellent science and path breaking innovations. With the need for sophistication required in multi-omics research, Chapter 5 focuses on innovative funding strategies such as crowdfunding and Angel philanthropy. Chapter 6 provides the latest advances in education innovation, the premise and reality of bioeconomy especially in a specific context of the developing world, not to mention the new concept of “social innovation” to link biomarkers with socially responsible and sustainable applications. Chapter 7, in ways similar to biomarkers, discusses the biosimilars as a field that has received much focus and prominence recently due to their immense potential in clinical and pharmaceutical innovation literatures. The broader goal post-biomarker discovery is to translate their use in clinics. However, the road from bench-to-bed side is arduous and complex that is subject to oversight from various national and international regulatory bodies. Chapter 8 underscores these regulatory science considerations and provides a concise overview on intellectual property rights in biomarker discovery. Thus, this book contributed by eminent biomarker scientists, clinicians, translational researchers and social scientists holistically covers the various facets of the biomarker discovery journey from “cell to society” in developing world. The lessons learned and highlighted here are of interest to the life sciences community in a global and interdependent world.
Описание: The COVID-19 pandemic caused by the SARS-CoV-2 virus has affected nearly every country and territory in the world. Although worldwide vaccination efforts have reduced the risk of serious disease outcomes, disparities in distribution have led to multiple waves of SARS-CoV-2 outbreaks and the emergence of variants of concern, some of which have enhanced infectivity and ability to evade existing vaccines. Hence there is an increasing interest in understanding the evolution of viruses like SARS-CoV-2, as well as improving our capacity to effectively current and manage future pandemics. This new volume reviews the most effective omic techniques for increasing our understanding of COVID-19, to improve diagnostics, prognostics, and genomic surveillance, and to facilitate development of effective treatments and vaccines. Chapters are written by an international team of experts and explore methods in the areas of genomics, transcriptomics, proteomics, and metabolomics. Techniques used to assess physiological function at the molecular level and artificial intelligence approaches used for more effective validation and translation of biomarker candidates into clinical use are also discussed. This book is an excellent resource for researchers studying biomarkers, virology, metabolic diseases, and infectious diseases, as well as clinical scientists, physicians, drug company scientists, and healthcare workers.
The high failure rate in the pharmaceutical industry has positioned biomarkers and personalized medicine in the frontline as possible solutions. If executed right, biomarkers and companion diagnostics (CDx) can potentially help the drug industry enhance the probability of success, accelerating time to market, and, more importantly, benefit patients by supporting accurate diagnosis and selection of the most effective and least toxic therapies. Biomarkers, Diagnostics, and Precision Medicine in the Drug Industry aims to examine the challenges and limitations in biomarkers and laboratory tests. It also offers advice on best practices to ensure proper application of biomarkers and bridges the gap between diagnostic business development claims and real-life deliverables. The book covers biomarkers for different purposes, provides examples from different technologies which includes standard-of-care approved assays as well as for-investigational-use and for-research-use-only assays. It also includes new data for biomarkers in different therapeutic indications and offers case studies and practical examples. Biomarkers, Diagnostics, and Precision Medicine in the Drug Industry serves as a reference to drug developers, IVD providers, healthcare givers, academics, and researchers for best practices to help increase the probability of success.
Provides the unique insight of an expert with extensive experience in diagnostics and clinical laboratory on one side and drug discovery and development on the other side
Addresses the challenges of drug development and precision medicine and suggests how to eliminate or mitigate these challenges through better utilization of biomarkers and diagnostics in drug development and patient management
Features case studies and real-life examples from different classes of biomarkers on different platforms for different therapeutic areas
Автор: Perneczky Название: Biomarkers for Alzheimer`s Disease Drug Development ISBN: 1493977032 ISBN-13(EAN): 9781493977031 Издательство: Springer Рейтинг: Цена: 11179.00 р. Наличие на складе: Есть у поставщика Поставка под заказ.
Описание:
PART I: The need for Alzheimer's Disease Biomarkers
1. Epidemiology of Dementia: The Burden on Society, the Challenges for Research
Frank J. Wolters and M. Arfan Ikram
2. Population-based Approaches to Alzheimer's Disease Prevention
Robert Perneczky
3. Systems Biology Methods for Alzheimer's Disease Research towards Molecular Signatures, Subtypes and Stages and Precision Medicine. Application in Cohort Studies and Trials
Juan I. Castrillo, Simone Lista, Harald Hampel, and Craig W. Ritchie
PART II: Innovative Approaches to Cerebrospinal Fluid Biomarker Discovery
4. CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform
Paul L. Wood and Randall L. Woltjer
5. CSF N-glycomics using MALDI MS Techniques in Alzheimer's Disease
Angelo Palmigiano, Angela Messina, Rosaria Ornella Bua, Rita Barone, Luisa Sturiale, Mario Zappia, and Domenico Garozzo
6. MicroRNA Profiling of Alzheimer's Disease Cerebrospinal Fluid Johannes Denk and Holger Jahn
Part III: Novel Blood-based Biomarkers
7. Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma
Jonathan Vogelgsang, Jens Wiltfang, and Hans-W. Klafki
8. Mass Spectrometry-based Metabolomic Multiplatform for Alzheimer's Disease Research
Raъl Gonzбlez-Domнnguez, Бlvaro Gonzбlez-Domнnguez, Ana Sayago, and Бngeles Fernбndez-Recamales
9. Blood-based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis within the Dimensional Spectrum of Neurodegenerative Diseases
Filippo Baldacci, Simone Lista, Sid E. O'Bryant, Roberto Ceravolo, Nicola Toschi, and Harald Hampel,
Part IV: Magnetic Resonance Imaging Methods
10. Functional Magnetic Resonance Imaging in Alzheimer' Disease Drug Development
Stefan Holiga, Ahmed Abdulkadir, Stefan Klцppel, and Juergen Dukart
11. Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies
Carles Falcon, Grйgory Operto, Josй Luis Molinuevo, and Juan Domingo Gispert
12. Hybrid PET-MRI in Alzheimer's Disease Research
Ismini C. Mainta, Maria I. Vargas, Sara Trombella, Giovanni B. Frisoni, Paul G. Unschuld, Valentina Garibotto
Part V: Molecular Imaging Approaches
13. Amyloid PET Imaging: Standardization and Integration with Other Alzheimer Disease Biomarkers
Silvia Morbelli and Matteo Bauckneht
14. The use of 18F-FDG PET in the Diagnostic Workup of Alzheimer's Dementia
Marion M. Ortner
15. Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography
Tessa Timmers, Bart N.M. van Berckel, Adriaan Lammertsma, and Rik Ossenkoppele
16. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach
Elena Rodriguez-Vieitez and Agneta Nordberg
Part VI: Neuropathology
17. Unbiased Lipidomics and Metabolomics of Human Brain Samples
Giuseppe Astarita, Matteo Stocchero, and Giuseppe Paglia
18. Neuropathological Assessment as an Endpoint in Clinical Trial Design
Steve Gentlemanand Alan King Lun Liu
Part VII Genomic Methods
19. Analysis of micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer's Disease Biomarker Discovery
Petros Takousis
20. Telomere length shortening in Alzheimer's disease - procedures for a causal investigation using single nucleotide polymorphisms in a Mendelian Randomization study Yiqiang Zhan,
ООО "Логосфера " Тел:+7(495) 980-12-10 www.logobook.ru
